No Data
Changzhou Qianhong BiopharmaLTD (SZSE:002550) Shareholders Are Still up 52% Over 3 Years Despite Pulling Back 6.5% in the Past Week
Solid Earnings May Not Tell The Whole Story For Changzhou Qianhong BiopharmaLTD (SZSE:002550)
Changzhou Qianhong Biopharma (002550.SZ): It is expected that the sales price of heparin active pharmaceutical ingredient will improve quarter-on-quarter in the fourth quarter.
Changzhou Qianhong Biopharma (002550.SZ) stated at an investor relations event on October 22 that in the third quarter of 2024, the sales volume of heparin active pharmaceutical ingredients increased significantly year-on-year, with gross profit and gross margin at historically high levels. However, export sales prices are still hovering at low levels, and there has been no significant fluctuation in foreign market demand. The number of slaughtered pigs in 2024 decreased by about 10% year-on-year. It is expected that the selling price of heparin active pharmaceutical ingredients will improve quarter-on-quarter in the fourth quarter, possibly showing a stable and upward trend.
Subdued Growth No Barrier To Changzhou Qianhong Biopharma CO.,LTD (SZSE:002550) With Shares Advancing 36%
Qianhong Pharmaceutical: Report for the third quarter of 2024
Changzhou Qianhong Biopharma (002550.SZ) announced its performance for the first three quarters, with a net income of 0.31 billion yuan, a year-on-year increase of 56.47%.
Changzhou Qianhong Biopharma (002550.SZ) released the third quarter report of 2024. In the first three quarters, the company achieved revenue...
Changzhou Qianhong Biopharma CO.,LTD's (SZSE:002550) Stock Going Strong But Fundamentals Look Weak: What Implications Could This Have On The Stock?
